RWE4Decisions REAL WORLD EVIDENCE

Symposium

Real-World Evidence for HTA/Payers Decision-Making

Policies & Partnerships

Co-moderated by **Karen Facey, Matti Aapro** and **Piia Rannanheimo**

Thursday, 24 November 2022 | 09.00-14.00 CET
Scotland House Brussels, Rond-Point Schuman 6, 1040 Brussels

PROGRAMME

9.00 REGISTRATION & WELCOME

9.30 INTRODUCTORY REMARKS

Jo De Cock, Administrateur Général Honoraire, Belgian Institute for Health and Disability Insurance (INAMI-RIZIV)

9.40 KEYNOTE PRESENTATIONS

Real-world data, the implementation of the European Health Data Space (EHDS) and HTA Regulations

Andrzej Rys, Principal Scientific Adviser, DG SANTE, European Commission (*video intervention*)

DARWIN EU – Progress update and deliverables

Xavier Kurz, Head of Data Analytics Workstream, Data Analytics and Methods Task Force, European Medicines Agency (EMA)

10.10 RECAP OF RWE4DECISIONS WORK IN 2022

Stakeholder views on the potential for policy to support development of real-world evidence (RWE) for decision-making

Karen Facey, Evidence Based Health Policy Consultant, RWE4Decisions Secretariat

Q&A with the audience

10.20 PANEL DISCUSSION: Will health data initiatives in the EU mean that payers and HTA bodies have better real-world evidence for decision-making?

*Co-Moderator: **Matti Aapro, MD**, Director at the Genolier Cancer Center, Switzerland*

Stakeholder reactions: Opportunities and challenges

- **Gözde Susuzlu Briggs**, Coordinator of "Data Saves Lives", European Patients' Forum
- **Alexander Natz,** Secretary-General, European Confederation of Pharmaceutical Entrepreneurs (EUCOPE)
- **Cláudia Furtado**, Head of the Health Technology Assessment, Pricing and Reimbursement Division, Portuguese Authority of Medicines and Health Products (INFARMED)
- **Robert Sauermann**, Deputy Head of Department of Pharmaceutical Affairs, Austrian Social Insurance and Chair of the Medicine Evaluation Committee (MEDEV)
- **Xavier Kurz**, Head of Data Analytics Workstream, Data Analytics and Methods Task Force, European Medicines Agency (EMA)

Discussion with the audience

11.00-11.20 | COFFEE BREAK

11.20 INTERACTIVE BREAKOUT ROOM DISCUSSIONS IN SMALL GROUPS

How do we work together to generate better real-world evidence for HTA bodies and Payers?

Moderated by RWE4Decisions Steering Group members

12.15 PANEL DISCUSSION WITH THE RWE4DECISIONS STEERING GROUP: Where does RWE4Decisions go from here?

*Co-Moderator: **Piia Rannanheimo**, Chief Specialist, Finnish Medicines Agency (Fimea)*

Plenary feedback from breakouts and discussion

- **Diane Kleinermans,** President of the Commission of Drugs Reimbursement, Belgian Institute for Health and Disability Insurance (INAMI-RIZIV)
- **Carlos Martín Saborido**, Health Economist Advisor, Spanish Ministry of Health
- **Simone Boselli**, EU Public Affairs Director, EURORDIS-Rare Disease Europe
- **Toon Digneffe**, Head Public Affairs & Partnerships, Europe and Canada, Takeda

12.55 CONCLUDING REMARKS & NEXT STEPS

Jo De Cock, Administrateur Général Honoraire, Belgian Institute for Health and Disability Insurance (INAMI-RIZIV)

13.00-14.00 | NETWORKING LUNCH

About the RWE4Decisions initiative

RWE4Decisions is a multi-stakeholder group, which has developed stakeholder actions that will better enable the use of real-world evidence in HTA/payer decisions about highly innovative technologies. The work has been commissioned by the Belgian National Institute of Health and Disability Insurance (INAMI-RIZIV) and contributors include HTA bodies and payers, regulatory agencies, patient groups, clinicians, industry and academic experts/researchers. FIPRA has facilitated the multi-stakeholder discussions with sponsorship by the European Confederation of Pharmaceutical Entrepreneurs (EUCOPE), AstraZeneca, Bayer, Boehringer Ingelheim, Novartis, Roche and Takeda.